INS and Alzheimer disease: The outcomes demonstrated an improvement in delayed memory in the 20 IU group (p < 0.05), as well as preserved caregiver-rated functional status at both insulin doses (p < 0.01) and general cognition assessed by the ADAS-cog score in the younger participants and functional abilities assessed by the ADCS-ADL scale for adults with AD (p < 0.05) [80].